# US 2004/0082034 A1 · Internal ribosome entry site of the labial gene for protein expression

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0082034 A1
- Document ID: US20040082034A1
- Status: Published application
- Kind: A1
- Application number: 10/614,282
- Filed: 2003-07-08
- Published: 2004-04-29
- Earliest claimed: 2002-07-09
- Assignees: National Health Research Institutes
- Inventors: Dung-Fang Lee; Jyh-Lyh Juang
- Web page: https://patentgrep.com/patent/US20040082034A1

## CPC

- C07K 14/43581: {from Drosophila}
- C12N 15/86: Viral vectors
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12N 2710/14143: viral genome or elements thereof as genetic vector
- C12N 2840/203: having an IRES
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention describes compositions and methods for recombinant protein expression in a wide range of cell types. The compositions comprise an IRES sequence from the Drosophila labial (lab) gene, or a variant or fragment thereof, or alternatively, a homolog of a lab IRES, or a variant or fragment thereof. Methods of using the compositions are also described.

## Claims

### Claim 1

A nucleic acid vector for the expression of at least two cistrons comprising:
a. a promoter operably linked to a nucleotide sequence comprising at least two cistrons; and
b. at least one nucleotide sequence comprising SEQ ID NO. 1, or a variant or fragment thereof operably linked to at least one of said at least two cistrons, wherein said nucleotide sequence comprising SEQ ID NO. 1, or variant or fragment thereof, provides IRES activity.

### Claim 2 (depends on 1)

The nucleic acid vector of claim 1, wherein at least one of said at least two cistrons comprises a reporter gene.

### Claim 3 (depends on 1)

The nucleic acid vector of claim 1, wherein at least one of said at least two cistrons comprises a therapeutic gene.

### Claim 4 (depends on 1)

A biological vector capable of expressing at least two cistrons comprising the nucleic acid vector of claim 1.

### Claim 5 (depends on 4)

The biological vector of claim 4, wherein said biological vector is selected from poxvirus, adenovirus, herpesvirus, adeno-associated virus, retrovirus, and baculovirus.

### Claim 6

A nucleic acid vector for the expression of at least two cistrons comprising:
a. a promoter operably linked to a nucleotide sequence comprising at least two cistrons; and
b. at least one nucleotide sequence comprising a homolog of SEQ ID NO. 1, or a variant or fragment thereof, operably linked to at least one of said at least two cistrons, wherein said homolog of SEQ ID NO. 1, or variant or fragment thereof, provides IRES activity.

### Claim 7 (depends on 6)

The nucleic acid vector of claim 6, wherein said homolog of SEQ ID NO. 1 comprises SEQ ID NO. 2.

### Claim 8 (depends on 6)

The nucleic acid vector of claim 6, wherein at least one of said at least two cistrons comprises a reporter gene.

### Claim 9 (depends on 6)

The nucleic acid vector of claim 6, wherein at least one of said at least two cistrons comprises a therapeutic gene.

### Claim 10 (depends on 6)

A biological vector capable of expressing said at least two cistrons comprising the nucleic acid vector of claim 6.

### Claim 11 (depends on 10)

The biological vector of claim 10, wherein said biological vector is selected from poxvirus, adenovirus, herpesvirus, adeno-associated virus, retrovirus, and baculovirus.

### Claim 12 (depends on 1)

A host cell comprising the nucleic acid vector of claim 1.

### Claim 13 (depends on 12)

The host cell of claim 12, wherein said host cell is an insect cell.

### Claim 14 (depends on 13)

The host cell of claim 13, wherein said insect cell is a Drosophila cell.

### Claim 15 (depends on 6)

A host cell comprising the nucleic acid vector of claim 6.

### Claim 16 (depends on 15)

The host cell of claim 15, wherein said host cell is a mammalian cell.

### Claim 17

A method for expressing at least two cistrons comprising: introducing into a host cell: a nucleic acid vector comprising
a. a promoter operably linked to a nucleotide sequence comprising at least two cistrons; and
b. at least one nucleotide sequence comprising SEQ ID NO. 1, or a variant or fragment thereof operably linked to at least one of said at least two cistrons, wherein said nucleotide sequence comprising SEQ ID NO. 1, or variant or fragment thereof, provides IRES activity.

### Claim 18

A method for expressing at least two cistrons comprising introducing into a host cell: a nucleic acid vector comprising
a. a promoter operably linked to a nucleotide sequence comprising at least two cistrons; and
b. at least one nucleotide sequence comprising a homolog of SEQ ID NO. 1, or a variant or fragment thereof operably linked to at least one of said at least two cistrons, wherein said homolog of SEQ ID NO. 1, or variant or fragment thereof provides IRES activity.

### Claim 19 (depends on 18)

The method of claim 18, wherein said homolog of SEQ ID NO. 1 comprises SEQ ID NO. 2.

### Claim 20

A baculovirus transfer vector for the expression of at least two cistrons comprising:
a. a polyhedrin promoter operably linked to a nucleotide sequence comprising at least two cistrons; and
b. at least one nucleotide sequence comprising SEQ ID NO. 1, or a variant or fragment thereof, operably linked to at least one of said at least two cistrons, wherein said nucleotide sequence comprising SEQ ID NO. 1, or variant or fragment thereof provides IRES activity.

### Claim 21 (depends on 20)

The baculovirus transfer vector of claim 20, wherein at least one of at least two cistrons comprises a reporter gene.

### Claim 22 (depends on 20)

The baculovirus transfer vector of claim 20, wherein at least one of at least two cistrons comprises a therapeutic gene.

### Claim 23

A recombinant baculovirus capable of expressing at least two cistrons in a host cell comprising a baculovirus genome comprising:
a. a polyhedrin promoter operably linked to a nucleotide sequence comprising at least two cistrons; and
b. at least one nucleotide sequence comprising SEQ ID NO. 1, or a variant or fragment thereof operably linked to at least one of said at least two cistrons, wherein said nucleotide sequence comprising SEQ ID NO. 1, or homolog, variant or fragment thereof, provides IRES activity.

### Claim 24 (depends on 20)

A method for producing a recombinant baculovirus capable of expressing at least two cistrons comprising:
a. introducing a baculovirus transfer vector of claim 20 and a baculovirus genomic DNA into a baculovirus host cell so as to effect homologous recombination; and
b. isolating a recombinant baculovirus.

### Claim 25 (depends on 24)

The method of claim 24, wherein said recombinant baculovirus is isolated by selecting plaques expressing at least one of said at least two cistrons.

### Claim 26 (depends on 23)

A baculovirus host cell expressing at least two cistrons comprising the recombinant baculovirus of claim 23.

### Claim 27

A baculovirus transfer vector for the expression of at least two cistrons comprising:
a. a polyhedrin promoter operably linked to a nucleotide sequence comprising at least two cistrons; and
b. at least one nucleotide sequence comprising a homolog of SEQ ID NO. 1, or a variant or fragment thereof, operably linked to at least one of said at least two cistrons, wherein said homolog, or variant or fragment thereof provides IRES activity.

### Claim 28 (depends on 27)

The baculovirus transfer vector of claim 27, wherein said homolog comprises SEQ ID NO.2.

### Claim 29 (depends on 27)

The baculovirus transfer vector of claim 27, wherein at least one of at least two cistrons comprises a reporter gene.

### Claim 30 (depends on 27)

The baculovirus transfer vector of claim 27, wherein at least one of at least two cistrons comprises a therapeutic gene.

### Claim 31

A recombinant baculovirus capable of expressing at least two cistrons in a host cell comprising a baculovirus genome comprising:
a. a polyhedrin promoter operably linked to a nucleotide sequence comprising at least two cistrons; and
b. at least one nucleotide sequence comprising a homolog of SEQ ID NO. 1, or a variant or fragment thereof operably linked to at least one of said at least two cistrons, wherein said homolog, or variant or fragment thereof, provides IRES activity.

### Claim 32 (depends on 31)

The recombinant baculovirus of claim 31, wherein said homolog comprises SEQ ID NO. 2.

### Claim 33 (depends on 27)

A method for producing a recombinant baculovirus capable of expressing at least two cistrons comprising:
a. introducing a baculovirus transfer vector of claim 27 and a baculovirus genomic DNA into a baculovirus host cell so as to effect homologous recombination; and
b. isolating a recombinant baculovirus.

### Claim 34 (depends on 33)

The method of claim 33, wherein said recombinant baculovirus is isolated by selecting plaques expressing at least one of said at least two cistrons.

### Claim 35 (depends on 31)

A baculovirus host cell expressing at least two cistrons comprising the recombinant baculovirus of claim 31.

### Claim 36 (depends on 1, 6)

A method of treating a patient comprising administering the nucleic acid vector of claim 1 or 6.

### Claim 37 (depends on 4, 10)

A method of treating a patient comprising administering the biological vector of claim 4 or 10.

### Claim 38 (depends on 1, 6)

A method of treating a patient comprising:
a. excising a cell or tissue from said patient;
b. introducing the nucleic acid vector of claim 1 or 6 into said excised cell or tissue; and
c. reimplanting said cell or tissue into said patient.

### Claim 39 (depends on 4, 10)

A method of treating a patient comprising:
a. excising a cell or tissue from said patient;
b. introducing the biological vector of claim 4 or 10 into said excised cell or tissue; and
c. reimplanting said cell or tissue into said patient.
